The difference between information and
expert, data-driven actionable intelligence
Welcome to the first issue of CMC Market Outlook
This monthly e-newsletter provides valuable insights for both buyers and sellers of CMC drug development services. Our coverage will help you identify and understand market trends that will inform your strategic business perspective.
Enjoy the December issue, and happy holidays!
Commercial Dose Manufacturing and Packaging:
PharmSource’s Database of Contract Service Providers includes 449 companies that provide commercial dose manufacturing and packaging services at sites around the world. In addition to commercial packaging, companies in this category offer commercial services including manufacture of injectables; non-sterile semi-solids and liquids; soft gelatin capsules; solid dosage forms; sterile non-injectable products; and transdermal dosage forms. This chart shows regional locations of companies offering these services:
|Region||Number of Commercial Dose Mfg + Pkg Service Providers|
This database provides company specifics, including contact information. Company capabilities are listed by site location, and include detailed capabilities information in many cases, including batch size ranges, potency types, packaging types, project acceptance criteria, GMP status, high containment capabilities, regulatory approvals and certifications and more.
A company in this category that was recently reported on in Bio/Pharmaceutical Outsourcing Report is Recipharm. Less than a year after its IPO, Recipharm made the news again when it… read on
Opportunity Knocks: In-Licensed Drug Products Can Signal Outsourcing Opportunity
Of the more than 230 New Molecular Entities (NMEs) approved between 2003-2013, over one-third were in-licensed by the sponsor receiving the approval. A significant difference in manufacturing status emerged between products originally discovered in-house and those in-licensed from external partners. During this period 66% of in-licensed NMEs were either outsourced completely or… More about this Trend Report
Bio/Pharma CapEx Trends: Sponsor Spending on In-House Capacity Trounces Outsourcing
• Analysis of recent trends in capital spending by bio/pharmaceutical companies and assesses the implications for the CMO industry
• Tracks spending by major segments of the bio/pharma industry, with detailed information on investments by global and generic bio/pharma companies
CMO Exits Reduce Pharma Manufacturing Capacity
by Jim Miller, President, PharmSource
The number of CMOs is shrinking due to acquisitions, exits, and compliance problems. Additional capacity is being lost as more CMOs pursue proprietary products to gain… read on
PharmSource STRATEGIC ADVANTAGE
PharmSource’s STRATEGIC ADVANTAGE service is the industry’s most respected outsourcing information web portal for serious consumers of information on contract drug development and manufacturing. Developed from PharmSource’s expert proprietary research, you won’t find this information in any other resource.
See for yourself how this resource gives you vital tools for understanding the industry.
To request a test-drive today, contact Katie Ludwick at firstname.lastname@example.org / 1-703-383-4903, ext. 112 (ET USA).